Citations

Mayo Clinic

Showing 10 of 108523 citations.

New (or not‐so‐new) tricks for old dogs: Ultrasound imaging in anatomy laboratories
Pawlina, Wojciech, Drake, Richard L.

Anatomical Sciences Education | April 24, 2015 | Volume: 8 | Issue: 3 | Pages: 195-196

10.1002/ase.1533 | PMID 25914351 Get It

A comparison of head dynamic response and brain tissue stress and strain using accident reconstructions for concussion, concussion with persistent postconcussive symptoms, and subdural hematoma
Karton, Clara , Hoshizaki, T. Blaine , Brien, Susan, Smith, Aynsley M., Smith, Aynsley, Oeur, Anna , Post, Andrew , Rousseau, Philippe , Marshall, Shawn , Cusimano, Michael D. , Gilchrist, Michael D.

Journal of Neurosurgery | April 24, 2015 | Volume: 123 | Issue: 2 | Pages: 415-422

10.3171/2014.10.jns14440 | PMID 25909574 Get It

OBJECT Concussions typically resolve within several days, but in a few cases the symptoms last for a month or longer and are termed persistent postconcussive symptoms (PPCS). These persisting symptoms may also be associated with more serious brain trauma similar to subdural hematoma (SDH). The objective of this study was to investigate the head dynamic and brain tissue responses of injury reconstructions resulting in concussion, PPCS, and SDH. METHODS Reconstruction cases were obtained from sports medicine clinics and hospitals. All subjects received a direct blow to the head resulting in symptoms. Those symptoms that resolved in 9 days or fewer were defined as concussions (n = 3). Those with symptoms lasting longer than 18 months were defined as PPCS (n = 3), and 3 patients presented with SDHs (n = 3). A Hybrid III headform was used in reconstruction to obtain linear and rotational accelerations of the head. These dynamic response data were then input into the University College Dublin Brain Trauma Model to calculate maximum principal strain and von Mises stress. A Kruskal-Wallis test followed by Tukey post hoc tests were used to compare head dynamic and brain tissue responses between injury groups. Statistical significance was set at p < 0.05. RESULTS A significant difference was identified for peak resultant linear and rotational acceleration between injury groups. Post hoc analyses revealed the SDH group had higher linear and rotational acceleration responses (316 g and 23,181 rad/sec2, respectively) than the concussion group (149 g and 8111 rad/sec2, respectively; p < 0.05). No significant differences were found between groups for either brain tissue measures of maximum principal strain or von Mises stress. CONCLUSIONS The reconstruction of accidents resulting in a concussion with transient symptoms (low severity) and SDHs revealed a positive relationship between an increase in head dynamic response and the risk for more serious brain injury. This type of relationship was not found for brain tissue stress and strain results derived by finite element analysis. Future research should be undertaken using a larger sample size to confirm these initial findings. Understanding the relationship between the head dynamic and brain tissue response and the nature of the injury provides important information for developing strategies for injury prevention.
Repeat resective surgery in complex pediatric refractory epilepsy: lessons learned
Bower, Regina S., Eckel, Laurence J. , Nickels, Katherine , Wetjen, Nicholas M. , Wirrell, Elaine , Wong‐Kisiel, Lily C. , Nickels, Katherine C

Journal of Neurosurgery: Pediatrics | April 24, 2015 | Volume: 16 | Issue: 1 | Pages: 94-100

10.3171/2014.12.peds14150 | PMID 25910035 Get It

OBJECT Resection can sometimes offer the best chance of meaningful seizure reduction in children with medically intractable epilepsy. However, when surgery fails to achieve the desired outcome, reoperation may be an option. The authors sought to investigate outcomes following resective reoperation in pediatric patients with refractory epilepsy, excluding tumoral epilepsies. Differences in preoperative workup between surgeries are analyzed to identify factors influencing outcomes and complications in this complex group. METHODS Medical records were reviewed for all pediatric patients undergoing a repeat resective surgery for refractory epilepsy at the authors' institution between 2005 and 2012. Tumor and vascular etiologies were excluded. Preoperative evaluation and outcomes were analyzed for each surgery and compared. RESULTS Ten patients met all inclusion criteria. The median age at seizure onset was 4.5 months. Preoperative MRI revealed no lesion in 30%. Nonspecific gliosis and cortical dysplasia were the most common pathologies. The majority of preoperative workups included MRI, video-electroencephalography (EEG), and SISCOM. Intracranial EEG was performed for 60% for the first presurgical evaluation and 70% for the second evaluation. The goal of surgery was palliative in 4 patients with widespread cortical dysplasia. The final Engel outcome was Class I in 50%. The rate of favorable outcome (Engel Class I–II) was 70%. The complication rate for the initial surgery was 10%. However, the rate increased to 50% with the second surgery, and 3 of these 5 complications were pseudomeningoceles requiring shunt placement (2 of the 3 patients underwent hemispherotomy). CONCLUSIONS Resective reoperation for pediatric refractory epilepsy has a high rate of favorable outcome and should be considered in appropriate candidates, even as a palliative measure. Intracranial EEG monitoring should be considered on initial workup in cases where the results of imaging or EEG studies are ambiguous or conflicting. Epilepsy secondary to cortical dysplasia, especially if the dysplasia is not seen clearly on MRI, can be difficult to cure surgically. Therefore, in these cases, as large a resection as can be safely accomplished should be done, particularly when the goal is palliative. The rate of complications, particularly pseudomeningocele ultimately requiring shunt placement, is much higher following reoperation, and patients should be counseled accordingly.
Arthroscopic Ligamentum Teres Reconstruction of the Hip in Ehlers-Danlos Syndrome: A Case Study
Hammarstedt, Jon E. , Redmond, John M., Gupta, Asheesh, Domb, Benjamin G.

HIP International | April 24, 2015 | Volume: 25 | Issue: 3 | Pages: 286-291

10.5301/hipint.5000228 | PMID 25907391 Get It

Background Ehlers-Danlos syndrome (EDS) is a genetic disorder that affects the structural integrity of collagen within the body. This presents clinically as a connective tissue disorder with increased elasticity of joints, muscles, and ligaments. Multiple joints are affected by hypermobility and joint injury is common in these patients. It is estimated that EDS occurs once in every 5,000 births worldwide. Case review This article focuses on reconstruction of the ligamentum teres (LT) of the hip using a tibialis anterior allograft to treat severe instability and pain in a 43 year-old female with EDS. The LT reconstruction was accompanied by labral repair and capsular plication. The patient was assessed pre- and postoperatively using modified Harris Hip Score (mHHS), Hip Outcome Score Activities of Daily Living (HOS-ADLS), Hip Outcome Score Sports Specific Subscale (HOS-SSS), Non Arthritic Hip Score (NAHS), Visual Analog Scale (VAS), and satisfaction. One year following surgery the patient has reported positive outcomes in terms of pain and instability. Literature review Ligament reconstruction has been reported in patients with Ehlers-Danlos syndrome for shoulders and knees with positive results and restoration of stability. Currently there is a paucity of literature regarding patients with EDS undergoing hip procedures. In addition, reconstruction of the ligamentum teres for hip instability and pain has rarely been reported in a normal patient cohort. Clinical relevance This is the first study to report ligamentum teres reconstruction of the hip in a patient with Ehlers-Danlos syndrome and hip instability. The patient demonstrated satisfactory results 1 year from surgery.
Immunogenetic control of the intestinal microbiota
Marietta, Eric, Rishi, Abdul , Taneja, Veena , Taneja, Veena

Immunology | April 24, 2015 | Volume: 145 | Issue: 3 | Pages: 313-322

10.1111/imm.12474 | PMID 25913295 Get It

SummaryAll vertebrates contain a diverse collection of commensal, symbiotic and pathogenic microorganisms, such as bacteria, viruses and fungi, on their various body surfaces, and the ecological community of these microorganisms is referred to as the microbiota. Mucosal sites, such as the intestine, harbour the majority of microorganisms, and the human intestine contains the largest community of commensal and symbiotic bacteria. This intestinal community of bacteria is diverse, and there is a significant variability among individuals with respect to the composition of the intestinal microbiome. Both genetic and environmental factors can influence the diversity and composition of the intestinal bacteria with the predominant environmental factor being diet. So far, studies have shown that diet‐dependent differences in the composition of intestinal bacteria can be classified into three groups, called enterotypes. Other environmental factors that can influence the composition include antibiotics, probiotics, smoking and drugs. Studies of monozygotic and dizygotic twins have proven that genetics plays a role. Recently, MHC II genes have been associated with specific microbial compositions in human infants and transgenic mice that express different HLA alleles. There is a growing list of genes/molecules that are involved with the sensing and monitoring of the intestinal lumen by the intestinal immune system that, when genetically altered, will significantly alter the composition of the intestinal microflora. The focus of this review will be on the genetic factors that influence the composition of the intestinal microflora.
Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial
Mueller, Christian, Neath, Sean‐Xavier , Christenson, Robert H. , McCord, James , Nowak, Richard M. , Vilke, Gary M. , Daniels, Lori B. , Hollander, Judd E. , Apple, Fred S. , Cannon, Chad , Nagurney, John T., Schreiber, Donald , Diercks, Deborah B. , Limkakeng, Alexander T. , Anand, Inder S. , Wu, Alan H.B. , Clopton, Paul , Jaffe, Allan S. , Peacock, W. Frank, Maisel, Alan S. , Shah, Kevin S , Marston, Nicholas , deFilippi, Christopher R. , Hogan, Christopher J. , Jaffe, Allan S. , Anand, Inder S , Daniels, Lori B

Academic Emergency Medicine | April 24, 2015 | Volume: 22 | Issue: 5 | Pages: 554-563

10.1111/acem.12649 | PMID 25908114 Get It

AbstractObjectivesChest pain is a common complaint to emergency departments (EDs) and clinical risk factors are used to predict which patients are at risk for worse outcomes and mortality. The goal was to assess the novel biomarker midregional proadrenomedullin (MR‐proADM) in prediction of mortality and major adverse cardiac events (MACE).MethodsThis was a subanalysis of the CHOPIN study, a 16‐center prospective trial that enrolled 2,071 patients presenting with chest pain within 6 hours of onset. The primary endpoint was 6‐month all‐cause mortality and the secondary endpoint was 30‐day and 6‐month MACE: ED visits or hospitalization for acute myocardial infarction, unstable angina, reinfarction, revascularization, and heart failure.ResultsMR‐proADM performed similarly to troponin (cTnI; c‐statistic = 0.845 and 0.794, respectively) for mortality prediction in all subjects and had similar results in those with noncardiac diagnoses. MR‐proADM concentrations were stratified by decile, and the cohort in the top decile had a 9.8% 6‐month mortality risk versus 0.9% risk for those in the bottom nine deciles (p < 0.0001). MR‐proADM, history of coronary artery disease (CAD), and hypertension were predictors of short‐term MACE, while history of CAD, hypertension, cTnI, and MR‐proADM were predictors of long‐term MACE.ConclusionsIn patients with chest pain, MR‐proADM predicts mortality and MACE in all‐comers with chest pain and has similar prediction in those with a noncardiac diagnosis. This exploratory analysis is primarily hypotheses‐generating and future prospective studies to identify its utility in risk stratification should be considered.
Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET)
McCarty, Todd P , Walsh, Thomas J. , Alexander, Barbara D. , Perl, Trish M. , Walker, Randall C., Schuster, Mindy G. , Lyon, G. Marshall, Wingard, John R. , Andes, David R. , Park, Benjamin J., Brandt, Mary E., Pappas, Peter G. , Investigators, TRANSNET, McCarty, T P , Walker, Randall, Baddley, John W. , Kontoyiannis, Dimitrios P. , Patterson, Thomas F. , Investigators, TRANSNET

Medical Mycology | April 24, 2015 | Volume: 53 | Issue: 5 | Pages: 440-446

10.1093/mmy/myv018 | PMID 25908651 Get It

Current approaches to atherosclerotic obstructive renal artery stenosis
Juncos, Luis I. , Textor, Stephen C., Textor, Stephen

Therapeutic Advances in Cardiovascular Disease | April 24, 2015 | Volume: 9 | Issue: 4 | Pages: 153-157

10.1177/1753944715579143 | PMID 25907506 Get It

Increased lifespan in the last few decades has substantially changed the scenario for renal artery stenosis. Indeed, because older populations show a higher prevalence of atherosclerotic disease, the incidence of atheromatous renal artery stenosis has also increased. Intuitively, one could surmise that stenosis removal should void both the hypertension and the kidney damage resulting from the obstructive stenosis. Surprisingly, a number of important clinical trials have failed to show the reversion seen in experimental models. The reasons for these differences may be linked to chronicity and inflammation associated with the atherosclerotic lesion. However, the failure to obtain a favorable response may also be related to abnormalities in the contralateral kidney. Indeed, this apparently normal kidney should work to compensate the hemodynamic effects of the ipsilateral stenosed kidney. Instead, structure and function in the contralateral kidney can be altered in renal artery stenosis to the point that this nonstenotic kidney may sustain both, hypertension and progressive kidney disease. Certainly, comparing the effects of clip removal in the Goldblatt model to angioplasty in clinical settings with atherosclerotic lesions may be totally inappropriate. Nevertheless, there remain certain clinical situations such as bilateral renal arterial disease, congestive heart failure, and progressive renal failure, where angioplasty may be an alternative. These approaches however are yet to be tested.
Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis
Hobson‐Webb, Lisa D., Hehir, Michael K. , Visser, Amy , Sanders, Donald B. , Burns, Ted M., Crum, Brian, Crum, Brian A.

Muscle & Nerve | April 23, 2015 | Volume: 52 | Issue: 2 | Pages: 211-215

10.1002/mus.24694 | PMID 25906756 Get It

ABSTRACTIntroduction: Mycophenolate mofetil (MMF) is frequently used to treat myasthenia gravis, but there is little information to guide clinicians on the safety of reducing the dose in well‐controlled patients. Methods: This retrospective chart review at 3 institutions identified 92 patients who had undergone MMF taper after achieving either pharmacologic remission or minimal manifestations status. Statistical analysis was performed to assess differences in patient characteristics between patients who had successfully tapered MMF and those who relapsed. Results: Of 92 patients undergoing a taper, 30 relapsed. The relapses were mild, transient, and usually responded to increased MMF dose. MG crisis did not occur. The mean dose at time of relapse was 888 mg/day. Patients with relapses were tapered more quickly (8.4 vs. 62.4 months). Conclusions: Tapering MMF appears safe after years of disease stability. Reducing the dose at a dose of only 500 mg/day every 12 months is recommended. Muscle Nerve 52: 211–215, 2015
Comment on Cefalu et al. The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action! Diabetes Care 2014;37:3137–3138
Yudkin, John , Montori, Víctor M. , Montori, Victor M

Diabetes Care | April 23, 2015 | Volume: 38 | Issue: 5 | Pages: e81-e81

10.2337/dc14-2910 | PMID 25908164 Get It